NorthWest Biotherapeutics Inc (NWBO)

[trocprofit]

Agreed. Simply parallel processes while getting to topline. Certainly speeds the process to approval (and revenue through UK Specials). To me it is crystal clear (tea leaves) that they are sitting on positive data or it would be corporate malfeasance to be spending money in a cart before the horse scenario for manufacturing. Not to mention we all know they would have had to announce negative data if that's what they are seeing. The paper, peer-review, and numerous consultants (SAB, Steering committee, etc.) is the reason for the delay. They could all come back to the table with their edits, findings, etc. at the same time and then we get topline. That is the wild card...along with whatever restrictions or rules from the Journal that accepts the article.